Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

AIFMD will not materially impact on Cayman Islands says Govier

Wednesday, October 26, 2011

amb
Paul Govier
By Beverly Chandler, Opalesque London:

Although law firm Maples has always been principally linked with the Cayman Islands, the firm also practices Irish and British Virgin Islands law and has a substantial office in London which it opened in 1997. Paul Govier, joint managing partner, London for Maples and Calder reports that it is the largest London office of any offshore firm, providing advice on Cayman Islands and BVI law on the ground in London.

Regulatory changes come and go but Cayman hangs onto its place as one of the most popular jurisdictions for hedge fund registration. Last year eight out of 10 of the top 10 fund launches were registered in the Cayman Islands and approximately 80% of European alternative funds use the Caymans for their fund vehicles.

Govier says: "The reasons that they choose Cayman now are the same reasons that they always have. Its a combination of a tried and tested product that works for managers, investors and prime brokers. They all understand how Cayman works and equally Cayman has designed its laws to work for these people. It is also partly inertia - its a herd mentality but for good reasons. You don't want to be distinguishing your fund vehicle on jurisdiction".

Govier believes that if you were looking to create an offshore jurisdiction, your wish list of features are all present in Cayman. "Political stability; English speaking; English law as the basis; tax neutrality; international best practice on anti m......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for